Clinical Trial

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 6, 2022 (before its estimated April 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma subjects with induction chemotherapy as bridging therapy.
Trial Details
NCT Number NCT05181501
Lead Sponsor Nanjing IASO Biotechnology Co., Ltd.
Conditions Multiple Myeloma
Enrollment 20 participants
Start Date 2022-04
Primary Completion 2024-04 (estimated)
Study Completion 2039-04 (estimated)
Updated on ClinicalTrials.gov 2022-01-06